SLC5A2 and heart failure: According to the ESC 2021 guidelines,7 a quadruple combination consisting of RASi, beta-blocker, MRA and SGLT-2 inhibitor was recommended for patients with HFrEF, to reduce the risk of heart failure hospitalisation and death.